695 related articles for article (PubMed ID: 18424268)
1. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
2. Strategies to cure experimental autoimmune colitis using antigen-specific Foxp3+ regulatory T cells.
de Zoeten EF; Hancock WW
Gastroenterology; 2008 Jun; 134(7):2171-4. PubMed ID: 18482583
[No Abstract] [Full Text] [Related]
3. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor.
Elinav E; Adam N; Waks T; Eshhar Z
Gastroenterology; 2009 May; 136(5):1721-31. PubMed ID: 19208357
[TBL] [Abstract][Full Text] [Related]
4. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.
Elson CO; Beagley KW; Sharmanov AT; Fujihashi K; Kiyono H; Tennyson GS; Cong Y; Black CA; Ridwan BW; McGhee JR
J Immunol; 1996 Sep; 157(5):2174-85. PubMed ID: 8757344
[TBL] [Abstract][Full Text] [Related]
5. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression.
Fantini MC; Rizzo A; Fina D; Caruso R; Sarra M; Stolfi C; Becker C; Macdonald TT; Pallone F; Neurath MF; Monteleone G
Gastroenterology; 2009 Apr; 136(4):1308-16, e1-3. PubMed ID: 19192480
[TBL] [Abstract][Full Text] [Related]
6. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis.
Totsuka T; Kanai T; Nemoto Y; Tomita T; Tsuchiya K; Sakamoto N; Okamoto R; Watanabe M
Eur J Immunol; 2008 May; 38(5):1275-86. PubMed ID: 18412161
[TBL] [Abstract][Full Text] [Related]
7. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells.
Fujimoto M; Nakano M; Terabe F; Kawahata H; Ohkawara T; Han Y; Ripley B; Serada S; Nishikawa T; Kimura A; Nomura S; Kishimoto T; Naka T
J Immunol; 2011 Jan; 186(1):32-40. PubMed ID: 21106853
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect.
Gotsman I; Shlomai A; Alper R; Rabbani E; Engelhardt D; Ilan Y
J Pharmacol Exp Ther; 2001 Jun; 297(3):926-32. PubMed ID: 11356912
[TBL] [Abstract][Full Text] [Related]
9. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
10. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
11. Jα33+ MAIT cells play a protective role in TNBS induced intestinal inflammation.
Ruijing X; Mengjun W; Xiaoling Z; Shu P; Mei W; Yingcheng Z; Yuling H; Jinquan T
Hepatogastroenterology; 2012 May; 59(115):762-7. PubMed ID: 22115767
[TBL] [Abstract][Full Text] [Related]
12. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
[TBL] [Abstract][Full Text] [Related]
13. B cells that produce immunoglobulin E mediate colitis in BALB/c mice.
Hoving JC; Kirstein F; Nieuwenhuizen NE; Fick LC; Hobeika E; Reth M; Brombacher F
Gastroenterology; 2012 Jan; 142(1):96-108. PubMed ID: 21983080
[TBL] [Abstract][Full Text] [Related]
14. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
[TBL] [Abstract][Full Text] [Related]
15. CD8+CD122+ regulatory T cells (Tregs) and CD4+ Tregs cooperatively prevent and cure CD4+ cell-induced colitis.
Endharti AT; Okuno Y; Shi Z; Misawa N; Toyokuni S; Ito M; Isobe K; Suzuki H
J Immunol; 2011 Jan; 186(1):41-52. PubMed ID: 21098236
[TBL] [Abstract][Full Text] [Related]
16. Polyclonal expansion of adoptively transferred CD4+ alpha beta T cells in the colonic lamina propria of scid mice with colitis.
Rudolphi A; Bonhagen K; Reimann J
Eur J Immunol; 1996 May; 26(5):1156-63. PubMed ID: 8647181
[TBL] [Abstract][Full Text] [Related]
17. Experimental inflammatory bowel disease--role of T cells.
Szczepanik M; Gryglewski A; Bryniarski K; Stachura J; Ptak W
J Physiol Pharmacol; 2000 Jun; 51(2):333-46. PubMed ID: 10898104
[TBL] [Abstract][Full Text] [Related]
18. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis.
Boirivant M; Amendola A; Butera A; Sanchez M; Xu L; Marinaro M; Kitani A; Di Giacinto C; Strober W; Fuss IJ
Gastroenterology; 2008 Nov; 135(5):1612-1623.e5. PubMed ID: 18765239
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
Gonzalez-Rey E; Delgado M
Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
